"Jan. 7, 2013 -- Children whose dads were depressed during the pregnancy are more likely to exhibit emotional and behavioral problems at age 3, new research suggests.
The finding comes from an ongoing study of more than 30,000 Norwegia"...
Mechanism of Action
Zingo™ delivers lidocaine hydrochloride monohydrate into the dermis. Lidocaine is an amide-type local anesthetic agent that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.
A single dose of Zingo™ (lindocaine hydrochloride monohydrate) in adults did not produce detectable plasma concentrations of lidocaine (limit of quantitation 5 ng/mL) in any subject tested (n = 38).
Application of Zingo™ (lindocaine hydrochloride monohydrate) to broken or inflamed skin, or multiple Zingo™ (lindocaine hydrochloride monohydrate) applications, could result in systemic plasma levels of lidocaine that could produce systemic toxicity.
When lidocaine is administered intravenously to healthy volunteers, the steady-state volume of distribution is approximately 0.8 to 1.3 L/kg. At much higher plasma concentrations (1 to 4 mcg/mL of free base) than those found following application of Zingo™ (lindocaine hydrochloride monohydrate) , the plasma protein binding of lidocaine is concentration dependent. Lidocaine crosses the placental and blood brain barriers, presumably by passive diffusion. CNS toxicity may typically be observed around 5000 ng/mL of lidocaine; however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL.
It is not known if lidocaine is metabolized in the skin. Lidocaine is metabolized rapidly by the liver to a number of metabolites including monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both of which have pharmacologic activity similar to, but less potent than that of lidocaine. The major metabolic pathway of lidocaine, sequential N-deethylation to monoethylglycinexylidide (MEGX) and glycinexylidide (GX), is primarily mediated by CYP1A2 with a minor role of CYP3A4. The metabolite, 2,6-xylidine, has unknown pharmacologic activity. Following intravenous administration of lidocaine, MEGX and GX concentrations in serum range from 11% to 36% and from 5% to 11% of lidocaine concentrations, respectively. Serum concentrations of MEGX are about one-third the serum lidocaine concentrations.
The half-life of lidocaine elimination from the plasma following intravenous administration is approximately 1.8 hours. Lidocaine and its metabolites are excreted by the kidneys. More than 98% of an absorbed dose of lidocaine can be recovered in the urine as metabolites or parent drug. Less than 10% of lidocaine is excreted unchanged in adults, and approximately 20% is excreted unchanged in neonates. The systemic clearance is approximately 8–10 mL/min/kg. During intravenous studies, the elimination half-life of lidocaine was statistically significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours).
Efficacy in Adults
The efficacy of Zingo™ (lindocaine hydrochloride monohydrate) in adults was evaluated in a randomized, double-blind, parallel-arm, sham-placebo controlled trial in which adult patients who required a venipuncture or peripheral venous cannulation received either Zingo™ (lindocaine hydrochloride monohydrate) or a sham placebo device.
Patients were treated with Zingo™ (lindocaine hydrochloride monohydrate) or a placebo device at the antecubital fossa or back of the hand, between one and three minutes prior to venipuncture or peripheral venous cannulation. Measurements of pain were made immediately following the procedure. Efficacy was measured using a continuous 100 mm visual analogue scale ranging from 0 (“no pain”) to 100 (“worst possible pain”).
Many of the patients had chronic medical problems such as depression, hypertension, hypothyroidism, and hyperlipidemia and over one fourth of the population may have been at higher than average risk of dermal bleeding due to use of concomitant medications such as NSAIDs, aspirin, and corticosteroids.
Treatment with active drug resulted in less pain compared with placebo (see Table 1).
Table 1: Visual Analogue Scale Score (Full Safety/Efficacy
(N = 345)
(N = 348)
|Adjusted Mean, LSM1||11.61||16.23|
|Difference in LSMs (SE2)||-4.62 (1.55)|
|95% Confidence Limits||-7.67, -1.57|
| 1 least squares mean
2 standard error
However, efficacy was primarily seen in patients undergoing venipuncture at the antecubital fossa, while patients undergoing cannulation at the back of the hand did not demonstrate a difference between active and sham administrations.
Efficacy in Pediatric Patients
The efficacy of Zingo™ (lindocaine hydrochloride monohydrate) in patients 3-18 years of age was evaluated in two randomized, double-blind, parallel-arm, sham-placebo controlled trials in which pediatric patients received either Zingo™ (lindocaine hydrochloride monohydrate) or a sham placebo device.
The overall patient population consisted of healthy pediatric patients as well as those with acute and chronic medical conditions (i.e., diabetes, asthma, seizure disorder, juvenile rheumatoid arthritis and renal or hepatic transplantation) ages 3-18 years. All patients required peripheral venipuncture or intravenous cannulation as part of their clinical care.
Two efficacy trials (Studies 1 and 2) were conducted during which patients were treated with Zingo™ (lindocaine hydrochloride monohydrate) or a placebo device at the back of hand or antecubital fossa, between one and three minutes prior to venipuncture or peripheral venous cannulation. Measurements of pain were made immediately following the venous procedure. Efficacy was measured using a modified version of the Wong-Baker FACES pain rating scale [a categorical 6-point scale containing 6 faces ranging from 0 (“no hurt”) to 5 (“hurts worst”)].
In both studies, treatment with active drug resulted in less pain, from venipuncture or peripheral IV cannulation, compared with placebo (See Table 2).
Table 2: Modified FACES Scale Score (ITT Population), Studies
1 and 2
|Study 1||Study 2|
(N = 292)
(N = 287)
(N = 269)
(N = 266)
|Difference in LSMs (SE2)||-0.33 (0.13)||-0.39 (0.13)|
|95% Confidence Limits||-0.58, -0.08||-0.65, -0.13|
|1 least squares mean
2 standard error
Last reviewed on RxList: 2/27/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Zingo Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Parenting and Pregnancy
Get tips for baby and you.